CELLASTRA INC
DELIVERING THE GENETIC CODE TO THE WOUND FOR SCAR-LESS HEALING
TARGETING GLOBAL UNMET NEEDS IN SURGERY, TRAUMA AND BURN INJURIES
CELLASTRA NEWS
CELLASTRA INC 12/15/2019
Cellastra announces results from in-vivo transgene expression of proprietary anti-scarring peptide.
Preparing for clinical study in burn injuries
San Francisco, CA, December 15, 2019 Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has obtained promising results for CELLEXA, a proprietary gene vector enabling in-vivo production of a potent anti-scarring peptide.
CELLASTRA'S STRATEGIC REPORT 01 /01/2020:
TOP GENE THERAPY COMPANIES
INVESTOR PRESENTATION JANUARY 2020 LINK
CELLASTRA INC 07/15/2019
Cellastra announces filing of global patent application for prevention of scars and adhesions.
CELLASTRA INC 06/24/2019
Cellastra announces collaboration with leading academic laboratory in Canada for manufacturing and testing of a novel gene vector programmed for scar prevention.
Preparing for clinical study in burn injuries
CELLASTRA INC 04/04/2019
Cellastra announces updates from American Burn Association's Annual Meeting in Las Vegas, April 2-5, 2019
Prof. Folke Sjoberg, Cellastra Scientific Advisory Board Memberawarded to give the Everett Idris Evans Memorial Lecture on frontiers in burn injury treatment
Cellastra prepares for clinical study in burn injury
